Thanks to #STATSummit for having our own Dr. Zachary J Roberts MD PhD, Head of R&D and Chief Medical Officer, discuss how we're pushing the boundaries of cell therapy, bringing treatments closer to home and into the first-line setting. Let’s continue breaking barriers and paving the way for the future of #CART. #celltherapy #immunotherapy Learn More: https://lnkd.in/eT8WT9Ar
Allogene Therapeutics
Biotechnology
South San Francisco, California 66,757 followers
About us
Allogene Therapeutics, with headquarters in South San Francisco, is a clinical-stage biotechnology company pioneering the development of allogeneic chimeric antigen receptor T cell (AlloCAR T™) products for cancer and autoimmune disease. For additional information on our guidelines, please visit www.allogene.com/news-center#community-guidelines Please be aware that the FBI recently issued a warning about an increased number of fake job postings for remote work employment that target applicants' personally identifiable information. All approved Allogene Therapeutics positions are accessible via the Allogene Careers page at www.allogene.com/careers.
- Website
-
www.allogene.com
External link for Allogene Therapeutics
- Industry
- Biotechnology
- Company size
- 201-500 employees
- Headquarters
- South San Francisco, California
- Type
- Public Company
- Founded
- 2017
- Specialties
- oncology, cancer, biotechnology, immunotherapy, CAR T, and autoimmune
Locations
-
Primary
210 E Grand Ave
South San Francisco, California 94080, US
-
7400 Gateway Blvd
Newark, California 94560, US
Employees at Allogene Therapeutics
Updates
-
Allogene is setting a higher bar for CLL treatment with our innovative ALPHA2 trial. By using healthy donor cells for #CART products, we aim to overcome limitations of autologous CAR T and provide a clinically meaningful advance for late-stage patients. #celltherapy #immunotherapy #STATSummit Learn How We Are Raising the Bar in CLL: Allogene.com/Pipeline
-
To close out #BloodCancerAwarenessMonth, Hua-Jay Cherng from Columbia joined Allogene’s CMO, Zach Roberts, to discuss the LBCL patient journey, unmet need in first-line consolidation care, and the importance of expanding access to potentially lifesaving products. Thank you Dr. Cherng for joining us! #CART #immunotherapy
-
At Allogene, we’ve rewritten the CAR T playbook. Our approach to development and trial design has the potential to deliver "off-the-shelf" #CART products that do what autologous CAR T therapies cannot. #celltherapy #immunotherapy #STATSummit Explore Innovation at Allogene: Allogene.com/Science
-
Looking forward to having our own Dr. Zachary Roberts, Head of R&D and Chief Medical Officer, join the 2024 STAT Summit to discuss new frontiers in #CART innovation. #celltherapy #immunotherapy #STATSummit Join Us: https://lnkd.in/gQj2wZEw
-
Thoroughly enjoyed participating in this lively panel discussion at the Fierce Biotech Summit in Boston. Biotech can be challenging work for communicators but there is no place we would rather be. #CART #celltherapy #immunotherapy $ALLO Learn more: https://lnkd.in/gtM6CwrF
-
As #BloodCancerAwareness Month comes to a close, we’d like to thank everyone who contributed and raised awareness. At Allogene, we continue to push forward towards our goals with patients at the forefront of our minds. Learn more about the potential of our lead investigational AlloCAR T™ product candidate available for front line #LBCL. #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: Allogene.com/Pipeline
-
We are looking forward to participating in Goldman Sachs Cell Therapy Day where our CEO, Dr. David Chang, will join a panel on innovations in the #allogeneic cell therapy landscape #CAR T. https://lnkd.in/gjGfcRdz
-
We’re pioneering a new approach to LBCL treatment with our groundbreaking ALPHA3 trial that aims to identify and treat patients as part of the 1L regimen, potentially transforming the standard of care. $ALLO #CART #celltherapy #immunotherapy Learn About the ALPHA3 Trial’s Groundbreaking Design: https://lnkd.in/gXiYrYPp
-
We look forward to presenting our first pre-clinical data highlighting the potential of ALLO-329, our allogeneic dual #CAR T for the treatment of #autoimmune diseases at the American College of Rheumatology (ACR) Convergence. #Immunotherapy #celltherapy https://lnkd.in/gPTr-nrh